Menu
GeneBe

DHFR

dihydrofolate reductase

Basic information

Region (hg38): 5:80626225-80654983

Links

ENSG00000228716NCBI:1719OMIM:126060HGNC:2861Uniprot:P00374AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • constitutional megaloblastic anemia with severe neurologic disease (Definitive), mode of inheritance: AR
  • constitutional megaloblastic anemia with severe neurologic disease (Moderate), mode of inheritance: AR
  • constitutional megaloblastic anemia with severe neurologic disease (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Megaloblastic anemia due to dihydrofolate reductase deficiencyARBiochemicalThe condition manifests with neurologic sequelae and megaloblastic anemia, and medical management (eg, with folinic acid) may help improve clinical parametersBiochemical; Hematologic; Neurologic21310276; 21310277

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the DHFR gene.

  • not provided (433 variants)
  • Hereditary cancer-predisposing syndrome (289 variants)
  • not specified (52 variants)
  • Endometrial carcinoma (47 variants)
  • Familial adenomatous polyposis 4 (13 variants)
  • Constitutional megaloblastic anemia with severe neurologic disease (10 variants)
  • MSH3-related condition (6 variants)
  • Inborn genetic diseases (6 variants)
  • Cavernous sinus meningioma (1 variants)
  • Gastrointestinal stromal tumor (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the DHFR gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
21
clinvar
1
clinvar
23
missense
30
clinvar
1
clinvar
31
nonsense
1
clinvar
1
start loss
0
frameshift
2
clinvar
2
inframe indel
0
splice donor/acceptor (+/-2bp)
2
clinvar
2
splice region
3
7
2
12
non coding
13
clinvar
19
clinvar
264
clinvar
174
clinvar
15
clinvar
485
Total 13 19 300 196 16

Highest pathogenic variant AF is 0.0000119

Variants in DHFR

This is a list of pathogenic ClinVar variants found in the DHFR region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
5-80629093-A-G Likely benign (Jul 26, 2018)761261
5-80629099-C-T Likely benign (Aug 19, 2022)2025038
5-80629101-C-T Uncertain significance (Jul 01, 2022)1994564
5-80629105-T-C Likely benign (Jan 10, 2024)2980516
5-80629138-C-T Likely benign (Oct 09, 2023)2825138
5-80629139-T-C Uncertain significance (Jan 07, 2022)2077587
5-80629150-G-A Likely benign (Apr 05, 2021)1542144
5-80629150-G-C Likely benign (Jun 16, 2023)2717847
5-80629166-C-A Uncertain significance (Nov 23, 2021)1501340
5-80629172-GA-G Benign (Mar 21, 2022)1968787
5-80629173-A-G Likely benign (Jun 13, 2022)2004850
5-80629179-T-A Likely benign (Mar 24, 2023)1667952
5-80629183-T-TAA Likely benign (Jul 12, 2022)1656037
5-80633863-A-C Likely benign (Nov 01, 2022)1655321
5-80633864-A-G Likely benign (Apr 29, 2023)2860523
5-80633865-C-T Likely benign (Mar 09, 2022)1557955
5-80633866-C-T Likely benign (Nov 13, 2023)1900518
5-80633867-T-G Likely benign (Dec 04, 2020)1658714
5-80633868-T-C Likely benign (Nov 07, 2023)2991030
5-80633869-A-G Likely benign (Oct 23, 2022)2014853
5-80633891-A-G Likely benign (Nov 20, 2023)1658200
5-80633904-T-A Constitutional megaloblastic anemia with severe neurologic disease Pathogenic (Feb 11, 2011)29674
5-80633914-G-C Uncertain significance (May 15, 2022)2110211
5-80633921-C-T Likely benign (Jan 08, 2024)723950
5-80633922-G-A Uncertain significance (Aug 19, 2023)1498012

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
DHFRprotein_codingprotein_codingENST00000439211 628756
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.03430.932125153091251620.0000360
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.016895.90.7090.000004251240
Missense in Polyphen1627.5480.5808352
Synonymous0.5502933.00.8780.00000154331
Loss of Function1.83410.40.3865.03e-7125

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.0001640.000163
Finnish0.000.00
European (Non-Finnish)0.00003540.0000353
Middle Eastern0.0001640.000163
South Asian0.00006740.0000653
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFR2. {ECO:0000269|PubMed:12096917, ECO:0000269|PubMed:21876188}.;
Pathway
Fluoropyrimidine Pathway, Pharmacodynamics;Antimetabolite Pathway - Folate Cycle, Pharmacodynamics;Folate biosynthesis - Homo sapiens (human);One carbon pool by folate - Homo sapiens (human);Methotrexate Pathway (Cancer Cell), Pharmacodynamics;Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics;Sepiapterin reductase deficiency;Segawa syndrome;Folate malabsorption, hereditary;Pterine Biosynthesis;Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);Methotrexate Action Pathway;Folate Metabolism;Dopa-responsive dystonia;Hyperphenylalaniemia due to guanosine triphosphate cyclohydrolase deficiency;Hyperphenylalaninemia due to 6-pyruvoyltetrahydropterin synthase deficiency (ptps);Hyperphenylalaninemia due to dhpr-deficiency;Fluoropyrimidine Activity;Folate Metabolism;Mitotic G1-G1-S phases;One Carbon Metabolism;Retinoblastoma (RB) in Cancer;Trans-sulfuration and one carbon metabolism;Ethanol effects on histone modifications;Nucleotide Metabolism;cell cycle: g1/s check point;Folate metabolism;Metabolism;Metabolism of folate and pterines;Activation of E2F1 target genes at G1/S;G1/S-Specific Transcription;dTMP <i>de novo</i> biosynthesis (mitochondrial);Mitotic G1-G1/S phases;Metabolism of water-soluble vitamins and cofactors;Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation;Metabolism of cofactors;Metabolism of vitamins and cofactors;G1/S Transition;Cell Cycle;Cell Cycle, Mitotic;E2F transcription factor network (Consensus)

Recessive Scores

pRec
0.662

Intolerance Scores

loftool
0.689
rvis_EVS
0.15
rvis_percentile_EVS
64.11

Haploinsufficiency Scores

pHI
0.591
hipred
N
hipred_score
0.373
ghis
0.541

Essentials

essential_gene_CRISPR
E
essential_gene_CRISPR2
E
essential_gene_gene_trap
E
gene_indispensability_pred
E
gene_indispensability_score
0.984

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Dhfr
Phenotype
growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); muscle phenotype; immune system phenotype; homeostasis/metabolism phenotype; cellular phenotype; liver/biliary system phenotype; embryo phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);

Zebrafish Information Network

Gene name
dhfr
Affected structure
somite border
Phenotype tag
abnormal
Phenotype quality
degenerate

Gene ontology

Biological process
regulation of transcription involved in G1/S transition of mitotic cell cycle;tetrahydrobiopterin biosynthetic process;one-carbon metabolic process;negative regulation of translation;axon regeneration;response to methotrexate;dihydrofolate metabolic process;tetrahydrofolate metabolic process;tetrahydrofolate biosynthetic process;folic acid metabolic process;positive regulation of nitric-oxide synthase activity;oxidation-reduction process;regulation of removal of superoxide radicals
Cellular component
cellular_component;mitochondrion;cytosol
Molecular function
translation repressor activity, mRNA regulatory element binding;mRNA binding;dihydrofolate reductase activity;folic acid binding;drug binding;folate reductase activity;NADP binding;methotrexate binding;NADPH binding;sequence-specific mRNA binding